RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Hepatitis (INACTIVE)

A collection of news and information related to Hepatitis (INACTIVE) published by this site and its partners.

Top Hepatitis (INACTIVE) Articles see all

Displaying items 1-5
  • Should prisoners get expensive hepatitis C drugs?

    WASHINGTON If used widely, a new generation of antiviral drugs has the potential to wipe out the deadly hepatitis C virus in the United States. But the high price of the drugs might prevent their use in prisons, which house as many as one-third of those who are infected.
  • Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

    Gilead Sciences' $84,000 price for hepatitis drug is scrutinized
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A....

    U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price

    U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company Thursday, Rep....

    Letters: Paying big bucks to Big Pharma

    Re "Prices of new drugs tough to take," March 10 I understand the necessity for drug companies to recoup research and development costs. But in regard to a medication that can cure hepatitis C, a spokesman for the maker of one drug that costs about $1,...

    Prices of new hepatitis C drugs are tough to swallow for insurers

    Prices of new hepatitis C drugs are tough to swallow for insurers
    A pair of new drugs to treat hepatitis C offer a cure for millions of Americans afflicted with the disease — but at a potentially staggering cost to taxpayers and health plans. Until now, therapies for hepatitis C helped only about half of...